12 important studies you may have missed from ASH Annual Meeting and Exposition

Healio provided comprehensive coverage of this year’s ASH Annual Meeting and Exposition.

Content includes stories about potentially practice-changing research, as well as perspective from key opinion leaders who discuss the implications of the findings.

blood1813410_640 — *Source: Adobe Stock.*

Here are 12 important studies from the meeting that may be relevant to your practice:

Hispanic individuals appeared considerably underrepresented in a large clinical trial of adolescents and young adults with acute lymphoblastic leukemia. However, Hispanic trial participants achieved outcomes comparable to those of non-Hispanic white participants, suggesting clinical trial participation may help mitigate racial and ethnic disparities in survival. Read more.
Second-line therapy with axicabtagene ciloleucel (Yescarta; Kite Pharma/Gilead Sciences) conferred a fourfold increase in EFS compared with standard-of-care treatment for diffuse large B-cell lymphoma. Read more.
Clonal hematopoiesis of indeterminate potential, which has been shown to substantially increase risk for blood cancer and cardiovascular disease, also appeared associated with protection from Alzheimer’s disease. Read more.
Patients with transfusion-dependent beta-thalassemia who received betibeglogene autotemcel (Zynteglo, bluebird bio) achieved durable transfusion independence with near-normal hemoglobin levels. Read more.
A once-monthly subcutaneous prophylaxis dose of fitusiran (Alnylam/Sanofi) appeared safe and effective for people with hemophilia A or B with inhibitors. Read more.
The addition of isatuximab (Sarclisa, Sanofi) to a standard three-drug induction regimen improved outcomes for certain patients with multiple myeloma. Read more.
The addition of polatuzumab vedotin (Polivy, Genentech) to chemotherapy significantly extended PFS compared with standard first-line treatment for patients with diffuse large B-cell lymphoma. Read more.
Second-line tisagenlecleucel (Kymriah, Novartis) failed to extend EFS compared with standard treatment for patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Read more.
Goals-of-care discussions often occur too late for patients with poor-prognosis, high-risk acute myeloid leukemia. More than half of all code status transitions occurred in the last 2 weeks of life. Read more.
Direct oral anticoagulant use appeared linked to high incidence of bleeding among patients with myeloproliferative neoplasms. Read more.
Older age, male sex, pre-COVID-19 prognosis of less than 6 months and deferral of ICU care appeared associated with greater risk for mortality among patients with blood cancer and COVID-19. Read more.
Upstream binding transcription factor tandem duplications, or UBTF-TDs, identified through integrated genomic analysis represent a new subtype of acute myeloid leukemia that previously had no known oncogenic driver. Read more.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Coverage

ASH Annual Meeting and Exposition

Read more

12 important studies you may have missed from ASH Annual Meeting and Exposition

Related Content